Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of Laquinimod Eye Drops
NCT05187403Phase 1Completed
- Sponsor
- Active Biotech AB
- Start
- Dec 2021
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of laquinimod in noninfectious uveitis (NIU) (4 arms), sponsored by Active Biotech AB. Primary endpoint: Adverse events at 7 days. Started Dec 2021; status: completed.
02
Drugs
laquinimod
03
Conditions
noninfectious uveitis (NIU)
Beyond the preview
Go deeper on NCT05187403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05187403.